(Q40146329)

17 September 2017

Levels of p27(kip1) determine Aplidin sensitivity (English)

1 reference

17 September 2017

2 references

1 reference

5

1 reference

17 September 2017

Juan F M Leal

3

0 references

Carmen Blanco-Aparicio

object named as

Carmen Blanco-Aparicio

4

0 references

Amancio Carnero

object named as

Amancio Carnero

9

0 references

author name string

Victoria Moneo

1

1 reference

17 September 2017

Beatriz G Serelde

2

1 reference

17 September 2017

Miguel Aracil

6

1 reference

17 September 2017

Juan C Tercero

7

1 reference

17 September 2017

José Jimeno

8

1 reference

17 September 2017

1 April 2007

1 reference

Molecular Cancer Therapeutics

17 September 2017

1 reference

17 September 2017

6

1 reference

17 September 2017

4

1 reference

17 September 2017

1310-1316

1 reference

How to decrease p27Kip1 levels during tumor development

17 September 2017

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Radiation-induced cell cycle arrest compromised by p21 deficiency

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

p38alpha MAPK is required for contact inhibition.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Oxidative stress and apoptosis

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Antitumor compounds from tunicates

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27(kip1) and Ras/p21(waf1) pathways

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Constitutive hyperexpression of p21(WAF1) in human U266 myeloma cells blocks the lethal signaling induced by oxidative stress but not by Fas.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Antiangiogenic activity of aplidine, a new agent of marine origin

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development

1 reference

12 April 2024

https://opencitations.net/index/api/v1/references/10.1158/1535-7163.MCT-06-0729

Identifiers

DOI

10.1158/1535-7163.MCT-06-0729

1 reference

17 September 2017

1 reference